secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001698530-24-000110
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure sells core SNA technology to Flashpoint for $1.5M; appoints new director
--------------------------------------------------------------------------------

- Sold spherical nucleic acid technology, R&D programs, and clinical assets to Flashpoint Therapeutics for $1.5 million gross proceeds.
- Will receive royalties on future licensing or sublicensing of the assets by Flashpoint.
- Board increased to seven; Eui Yull Hwang appointed as independent Class II director.
- No material relationship exists between Exicure and Flashpoint aside from the transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853024000110/0001698530-24-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853024000110/xcur-20240930.htm
  HTML page:      https://secwatch.observer/filing/0001698530-24-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer